Psychedelics, particularly psilocybin, have gained mainstream attention due to their therapeutic potential. Clinical trials focus on safety, dosage, and efficacy. Regulatory approval remains a challenge due to legal restrictions. Companies like Compass Pathways and Cybin are advancing in phase 3 trials.